Gut radiation may revive immunotherapy in resistant cancers

NCT ID NCT06076135

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This phase 2 trial investigates whether a single, low dose of radiation to the small intestine can help the immune system recognize and attack tumors again in people with advanced solid cancers that have stopped responding to immunotherapy. Participants receive 1Gy of radiation to the jejunum and ileum, followed by their previous or adjusted PD-1/PD-L1 inhibitor. The study aims to see if this combination can shrink tumors or slow disease progression, and it also collects blood and stool samples to explore why some patients respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
low-dose radiation to the intestine (1Gy) plus PD-1/PD-L1 inhibitors
What this could lead to
If successful, this approach could offer a new way to re-sensitize tumors that have stopped responding to immunotherapy, potentially improving outcomes for patients with advanced cancer.
What could go wrong
This is a small, early-phase trial (24 participants) and the combination may not work for everyone. There is also a risk of side effects from both radiation and immunotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT BLOCKADE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cancer Hospital, Shantou University Medical College

    Shantou, Guangdong, 515031, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.